Company Outlook & Guidance: Capital allocation on two fronts - R&D and the acquisition of Viatris - has resulted in returns ratios falling below ~10% despite the growth in the business. A huge looming net debt of $1.4 Bn could lead to further stake dilution in Biocon biologics.